5 Best Safest Stocks To Buy For 2014

Analysts today were reflecting on the war of words inside, and outside, of J.C. Penney (JCP), with activist investor Bill Ackman of Pershing Square Capital, and the company’s board, both releasing public statements in the last 24 hours attacking one another’s handling of the search for a new chief executive.

CNBC’s David Faber reported a short while ago that Perry Capital, a 7% holder, is going to file a 13-D later today asking the company to immediately move to replace Mike Ullman as interim CEO with former CEO Allen Questrom as chair and Ken Hicks, head of FootLocker (FL) as CEO.

Penney shares are down 75 cents, or 6%, at $12.91.

Credit Suisse’s Michael Exstein, reiterating an Underperform rating on the stock, and a $15 price target, writes this morning that the battle is “Just what JC Penney does not need,” as “The very public debate around Mr. Ullman’s tenure will only make it more difficult to attract senior level executives to JC Penney.”

5 Best Safest Stocks To Buy For 2014: Rockwell Automation Inc(ROK)

Rockwell Automation, Inc. provides industrial automation power, control, and information solutions. It operates in two segments, Architecture and Software, and Control Products and Solutions. The Architecture and Software segment offers control platforms that perform multiple control disciplines and monitoring of applications, including discrete, batch and continuous process, drives control, motion control, and machine safety control; and products comprising controllers, electronic operator interface devices, electronic input/output devices, communication and networking products, and industrial computers. This segment also offers software products, such as configuration and visualization software used to operate and supervise control platforms, advanced process control software, and manufacturing execution software to enhance manufacturing productivity and meet regulatory requirements; and rotary and linear motion control products, and sensors and machine safety components . The Control Products and Solutions segment provides low and medium voltage electro-mechanical and electronic motor starters, motor and circuit protection devices, AC/DC variable frequency drives, push buttons, signaling devices, termination and protection devices, relays and timers, and condition sensors; and packaged solutions, such as configured drives and motor control centers to automation and information solutions, as well as life-cycle support services. The company sells its products, solutions, and services primarily under the Rockwell Automation, Allen-Bradley, A-B, and Rockwell Software brand names to the food and beverage, transportation, oil and gas, metals, mining, home and personal care, pulp and paper, and life sciences markets through independent distributors and direct sales force in the United States, Canada, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Rockwell Automation, Inc. was founded in 1928 and is headquartered in Milwauke e , Wisconsin.

Advisors’ Opinion:

  • [By John Kell]

    Rockwell Automation Inc.(ROK) said its fiscal first-quarter earnings jumped 23% as operating margins widened and sales in both segments increased. Results topped estimates, pushing shares up 2.6% to $118 premarket.

  • [By Ben Levisohn]

    That negative sentiment “flashed as a positive indicator,” Inch and Lau say, and some stocks appear to be “‘locked and loaded’ to meaningfully exceed forecast estimates.” Those include Rockwell Automation (ROK), Eaton (ETN) and Emerson Electric (EMR).

  • [By Ben Levisohn]

    Barclays’ Scott Davis and team believe it might be, and for evidence they look at 3M (MMM), Emerson Electric (EMR), Rockwell Automation (ROK), and MSC Industrial Direct (MSM). They write:

  • [By Marc Bastow]

    Industrial automation power, control and information systems company Rockwell Automation (ROK) raised its quarterly dividend 12% to 58 cents per share, payable on Dec. 10 to shareholders of record as of Nov. 8.
    ROK Dividend Yield: 2.08%

5 Best Safest Stocks To Buy For 2014: Fleetmatics Group PLC (FLTX)

Fleetmatics Group PLC (FleetMatics), incorporated on October 28, 2004, is a provider of fleet management solutions delivered as software-as-a-service (SaaS). The Company offers Web-based and mobile application solutions, which provide fleet operators with visibility into vehicle location, fuel usage, speed and mileage and other insights into their mobile workforce. The Company offers fleet management software solutions. The Company’s FleetMatics-branded solutions sold under the FleetMatics or SageQuest names. Its solutions are accessed through a Web browser or mobile application and provide its customers with actionable business intelligence. Its SaaS offering consists of the easy-to-use components: Tracking Alerts, Route Replay, Geofencing and Landmarks, FleetTracking Dashboard, Fleet Reports, Mobile App, Speed Limits, Panoramic Reporting and Benchmarking. In addition to this core SaaS offering, it also offers the additional features to its customers: Fuel Card Reportin g Integration, FleetMatics Fuel Card and Navigation Unit Integration. Effective August 8, 2013, Fleetmatics Group PLC a unit of Fleetmatics Investor Holdings LP, acquired Connect2Field Holdings Pty Ltd.

The Company’s Fleet Tracking Alerts allow fleet operators to set driver performance thresholds and receive e-mail notifications when unwanted driving behavior occurs. Notifications are sent when a vehicle enters or exits specified areas, moves during specified times, or when a vehicle’s speed or idle time exceeds specified thresholds. Its Route Replay feature allows customers to play back each journey taken by their vehicles, from start up to shut down and provides customers with minute-by-minute location and speed details. Fleet operators can start, stop, pause, and change the speed of the journey replay using intuitive playback controls to monitor and analyze driver behavior. Integration with Google Maps enables customers to pinpoint vehicle location with s atellite, street views and zooming capabilities.

The Company’s Geofencing and Landmarks feature allows customers to designate areas on the map, in which vehicles are allowed or not allowed to travel. Fleet operators receive notifications when a vehicle enters or exits an unauthorized location and reports are generated detailing time spent in unauthorized areas. Its FleetTracking Dashboard provides fleet operators with a way to monitor overall fleet performance through a graphical summary. This interface allows fleet operators to evaluate performance categories across their fleet, including speed, engine on-time, vehicle idling, vehicle mileage and number of stops. Fleet operators can also view individual vehicle performance.

The Company provides its customers with over 40 pre-built on-demand reports, which they can access to analyze fleet data. Its reports contain information about vehicle movement and use, including vehicle location, ignition on and off time, engine idle time, arrival and departure times, distance traveled, hours worked, and vehicle speed. Its Mobile App is a portable software application, which fleet operators can use to access actionable business intelligence and insights over mobile devices. It includes the FleetTracking Dashboard, Reports, Tracking Alerts, Route Replay, and Geofencing and Landmarks.

With the Company’s Speed Limits feature, the Company provides a range of speed limit information across all types of roads and geographies, including local and residential roads. Speed limit is powered by FleetMatics RoadSpeed, a specialized database of average speed values derived from billions of points of vehicle movement. Its panoramic reporting engine features in-depth historical trending analyses and strategic comparative information from the customers, such as driver and organizational performance benchmarking. Its Fuel Card Reporting Integration feature integrates customers’ fuel card usage information into its fleet management softwa re platform. It provides its customers with an on-demand fue! l usage s! ummary for an entire fleet, as well as detailed information on individual vehicles. Reports are generated, which compare fuel purchases with vehicle location data.

The Company has partnered with an independent global fleet card provider to deliver a Universal Platinum MasterCard. Its Navigation Unit Integration features with Garmin global positioning system (GPS) navigation devices, streamlines dispatching and communication by integrating its fleet management software with its customers’ GPS navigation devices. It provides customers with turn-by-turn directions, notification of job status, estimated time of arrival to the next job site, and easy-to-use messaging capabilities. Drivers receive automatic job updates, eliminating the need to manually enter addresses while driving. It offers customers the choice of two fleet management branded solutions, FleetMatics and SageQuest.

Advisors’ Opinion:

  • [By John Kell]

    FleetMatics Group Ltd.’s(FLTX) fourth-quarter earnings more than tripled as a tax benefit helped boost the bottom line, along with a jump in revenue. However, shares slumped 18% to $32.60 premarket as the company’s earnings outlook fell markedly short of Wall Street’s expectations.

  • [By Louis Navellier]

    Fleetmatics Group (FLTX) is another Europe stock with the characteristics needed to be a leader in the European markets this year. The company makes software that allows operators of commercial vehicle fleets to track vehicles and learn about vehicle location, fuel usage, speed and mileage. The Irish company has seen earnings explode this year with growth of more than 700% in bottom-line profit increases.

5 Best Safest Stocks To Buy For 2014: Panasonic Corp (PCRFF)

Panasonic Corporation is a Japan-based electronics manufacturer. The Audio-Visual Computer (AVC) Network segment offers audio and video equipment. The Appliance segment provides household air-conditioning machines. The System Communications segment provides system network and mobile communications-related products and services. The Eco-solutions segment consists of riding, energy system, housing system and others. The Automotive systems segment provides automotive multimedia-related equipment and others. The Device segment provides electronic components, semiconductors and optical devices. The Energy segment provides solar system and lithium-ion batteries. The Others segment consists of health care, manufacturing solutions and PanaHome. On October 1, 2013, it announced it had set up a research and development center in Singapore. In December 2013, it transferred its 66.7% stake in a Japan-based subsidiary. In December 2013, it acquired a Turkey-based company. Advisors’ Opinion:

  • [By MARKETWATCH]

    LOS ANGELES (MarketWatch) — Japanese stocks slipped early Monday, with the Nikkei Stock Average (JP:NIK) down 0.1% at 14,298.17, and the Topix dropping 0.4%. Singapore-traded lead futures for the Nikkei Average had suggested a 0.8% gain for the index, but the indicator fell after the Cabinet Office reported fourth-quarter economic growth of 0.3%, flat from the previous quarter and below expectations in separate Reuters and Wall Street Journal/Nikkei surveys. The disappointing economic data also pushed the yen higher, weighing on some exporters, with Panasonic Corp. (JP:6752) (PCRFF) down 1.8%, NEC Corp. (JP:6701) (NIPNF) off 1.3%, and Sony Corp. (JP:6758) (SNE) down 0.7% after S&P downgraded the firm’s credit rating to BBB- from BBB with a negative outlook. Shares of Internet retailer Rakuten Inc. (JP:4755) (RKUNF) dropped 12% after announcing plans to buy online messaging and telecom firm Viber Media Inc. for $900 million as well as posting below-consensus full-year profit. Banks were broadly lower, with Mizuho Financial Group Inc. (JP:8411) (MFG) off 1% and Sumitomo Mitsui Financial Group Inc. (JP:8316) (SMFG) off 1.1%, though Daiwa Securities Group Inc. (JP:8601)

  • [By Victor Selva]

    Of course, a great bet also involves many risks. Even though LCD technology became very popular in these last few years, both in TV screens and computer monitors, we should never miss the fact that technological markets are often exposed to products becoming obsolete due to the development of new, more efficient technology. Without going any further, it’s easy to recall the plasma display panel (PDP) fiasco, an apparently promising market in the 1990s and early 2000s but quickly replaced by LCDs (by 2008 LCDs sell 21.1 million units, almost 10 times PDP sales on the same year). Even Panasonic Corporation (PCRFF) announced it will interrupt production of PDP on 2014.

  • [By Jesse Solomon]

    And while competitors Panasonic (PCRFF), Row 44 and Viasat are vying for in-flight wi-fi space, many of Gogo’s clients — which include Delta (DAL, Fortune 500), American (AAMRQ, Fortune 500), and Virgin America — have contracts until 2018, according to Schildkraut.

  • [By MARKETWATCH]

    LOS ANGELES (MarketWatch) — A rising Japanese yen and weak results from Caterpillar Inc. (CAT) overnight sent Tokyo-listed shares lower in early Thursday trade, with the Nikkei Stock Average (JP:NIK) falling 0.4% to 14,363.59, while the Topix also lost 0.4%. With the U.S. dollar remaining below the 98-yen level amid concerns about the health of China’s largest banks, some currency-sensitive shares extended their losses after driving the Nikkei Average down 2% in the previous session. Among them, trading house Mitsui & Co. (JP:8031) (MITSY) fell 1.3%, retail major J. Front Retailing Co. (JP:3086) lost 1.2%, auto maker Nissan Motor Co. (JP:7201) (NSANY) retreated 0.6%, and Fujitsu Ltd. (JP:6702) (FJTSY) traded 1% lower. The below-forecast quarterly results and outlook cut from U.S. construction-equipment maker Caterpillar sent its Japanese rivals tumbling, with Komatsu Ltd. (JP:6301) (KMTUF) dropping 3.5% and Hitachi Construction Macheriny Co. (JP:6305) (HTCMF) falling 3.1%. On the upside, Hitachi Ltd. (JP:6501) (HTHIF) soared 5.4% after raising its profit and revenue guidance for the fiscal first hal

5 Best Safest Stocks To Buy For 2014: Forest Laboratories Inc (FRX)

Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician’s prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company’s principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer’s disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor ( SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.

Aclidinium

In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback s ystem which, through a ‘colored control window’ and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.

Linaclotide

Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.

Viibryd

As a result of its acquisition of Clinical Data, Inc. (Clinical Data) complet ed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.

Daliresp

In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.

Namenda

Namenda (memantine HCl) is an N -methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer’s disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer’s type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.

Bystolic

Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).

Savella

Savella (milnacipran HCl) is the Company’s selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pa in and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.

Teflaro

In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.

Avibactam

Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.

Lexapro

Lexapro’s is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro’s (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.

Cariprazine

Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also und ergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.

Levomilnacipran

Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.

GRT 6005

In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.

TTP399

In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.

Azimilide

In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA ag reed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.

RGH-618

RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.

Advisors’ Opinion:

  • [By CNNMoney Staff]

    Actavis (ACT, Fortune 500) shares were up after it said earnings doubled in the fourth quarter. The company announced plans earlier this week to buy Forest Laboratories (FRX) for $25 billion. Forest shares were also higher.

  • [By Lauren Pollock]

    Among the companies with shares expected to actively trade in Tuesday’s session are Forest Laboratories Inc.(FRX), Coca-Cola Co.(KO) and Waste Management Inc.(WM)

  • [By Jake L’Ecuyer]

    Leading and Lagging Sectors
    Tuesday morning, the healthcare sector proved to be a source of strength for the market. Healthcare stocks surged 1% in today’s trading. Leading the sector was strength from Forest Laboratories (NYSE: FRX) and Chindex International (NASDAQ: CHDX) on acquisition news.

  • [By Jake L’Ecuyer]

    Leading the sector was strength from Forest Laboratories (NYSE: FRX) and Chindex International (NASDAQ: CHDX) on acquisition news. In trading on Tuesday, non-cyclical consumer goods & services shares were relative laggards, down on the day by 0.2%.

5 Best Safest Stocks To Buy For 2014: Hanesbrands Inc. (HBI)

Hanesbrands Inc., a consumer goods company, engages in the design, manufacture, sourcing, and sale of apparel essentials in the United States and internationally. Its product portfolio includes T-shirts, bras, panties, men?s underwear, kids? underwear, casualwear, activewear, socks, and hosiery. The company offers its products under the brand names of Hanes, Champion, Playtex, Bali, L?eggs, Just My Size, barely there, Wonderbra, Stedman, Outer Banks, Zorba, Rinbros, and Duofold. Hanesbrands also licenses its Champion name for collegiate apparel and footwear. The company sells its products through various distribution channels, which include mass merchants, national chains and department stores, direct to Consumer, and other retail channels, such as embellishers, specialty retailers, and sporting goods stores. As of January 2, 2010, it operated 228 outlet stores. The company is headquartered in Winston-Salem, North Carolina. Hanesbrands Inc. operates independently of Sara L ee Corp. as of September 5, 2006.

Advisors’ Opinion:

  • [By , Zacks Investment Research]

    Investors seeking exposure to the ‘Apparel’ industry could look at HanesBrand (HBI), a Zacks Rank #1 (Strong Buy) stock.

    Want the latest recommendations from Zacks Investment Research? Today, you can download7 Best Stocks for the Next 30 Days.Click to get this free report >>

  • [By Marc Bastow]

    The biggest increase among our dividend stocks this week was a tie between two companies, including consumer apparel brands manufacturer Hanesbrand (HBI), which raised its quarterly dividend 50% to 30 cents per share, payable on Mar. 11 to shareholders of record as of Feb. 18.
    HBI Dividend Yield: 1.68%

  • [By Richard Moroney]

    When HanesBrands (HBI) initiated a quarterly dividend in April, the underwear maker said the move reflected its debt-reduction progress, cash-flow growth, and margin-improvement prospects.